Inmune Bio, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On October 27, 2026, INmune Bio (a $51M market-cap company) sold 3,000,000 common shares at $1.50/share for $4.5M aggregate proceeds, plus issued warrants to purchase 3,000,000 additional shares at $1.65 exercise price, 100% warrant coverage. Warrants exercisable from April 27, 2027 through April 27, 2032. Shares sold registered under Form S-3; warrants/warrant shares issued under Rule 506(d) exemption. No specific purchaser counterparty named in agreement template.
Why this rating
Raises ~$4.5M (8.8% of market cap); meaningful capital infusion but not transformational. Dilutive warrant structure common in micro-cap financings.
Price action (we called it positive)
before filing · preread $1.52 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.